Mizuho initiated coverage of Tarsus Pharmaceuticals (TARS) with an Outperform rating and $100 price target Tarsus is a commercial stage, ophthalmology-focused company that markets Xdemvy, the only approved treatment for Demodex blepharitis, the analyst tells investors in a research note. The firm projects peak Xdemvy sales in DB of over $2B. Mizuho’s physician survey supports the bullish view, it says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $51 from $45 at Goldman Sachs
- Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Tarsus Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
- Strong Market Position and Growth Potential Drive Buy Rating for Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth